<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240907205245&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;v=2.18.0.post9+e462414&amp;ff=20240907205245&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 08 Sep 2024 00:52:46 +0000</lastbuilddate>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>A focus on two rapidly expanding fields: cardio-oncology and genetics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39242083/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 7;45(34):3095-3099. doi: 10.1093/eurheartj/ehae556.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39242083/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39242083</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae556>10.1093/eurheartj/ehae556</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39242083</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>A focus on two rapidly expanding fields: cardio-oncology and genetics</dc:title>
<dc:identifier>pmid:39242083</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae556</dc:identifier>
</item>
<item>
<title>A systems view of the vascular endothelium in health and disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241746/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>The dysfunction of blood-vessel-lining endothelial cells is a major cause of mortality. Although endothelial cells, being present in all organs as a single-cell layer, are often conceived as a rather inert cell population, the vascular endothelium as a whole should be considered a highly dynamic and interactive systemically disseminated organ. We present here a holistic view of the field of vascular research and review the diverse functions of blood-vessel-lining endothelial cells during the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4833-4858. doi: 10.1016/j.cell.2024.07.012.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The dysfunction of blood-vessel-lining endothelial cells is a major cause of mortality. Although endothelial cells, being present in all organs as a single-cell layer, are often conceived as a rather inert cell population, the vascular endothelium as a whole should be considered a highly dynamic and interactive systemically disseminated organ. We present here a holistic view of the field of vascular research and review the diverse functions of blood-vessel-lining endothelial cells during the life cycle of the vasculature, namely responsive and relaying functions of the vascular endothelium and the responsive roles as instructive gatekeepers of organ function. Emerging translational perspectives in regenerative medicine, preventive medicine, and aging research are developed. Collectively, this review is aimed at promoting disciplinary coherence in the field of angioscience for a broader appreciation of the importance of the vasculature for organ function, systemic health, and healthy aging.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241746/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39241746</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.012>10.1016/j.cell.2024.07.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241746</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Hellmut G Augustin</dc:creator>
<dc:creator>Gou Young Koh</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>A systems view of the vascular endothelium in health and disease</dc:title>
<dc:identifier>pmid:39241746</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.012</dc:identifier>
</item>
<item>
<title>Laws of thought in living cells</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241745/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>Building biological computers is one of the most intensively pursued goals of modern synthetic biology. The new TriLoS tristate-based logic synthesis platform, published in this issue of Cell, offers a long-awaited solution to scale up the complexity of biocomputing, opening a path to move this field beyond proof-of-principle demonstrations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4830-4832. doi: 10.1016/j.cell.2024.08.005.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Building biological computers is one of the most intensively pursued goals of modern synthetic biology. The new TriLoS tristate-based logic synthesis platform, published in this issue of Cell, offers a long-awaited solution to scale up the complexity of biocomputing, opening a path to move this field beyond proof-of-principle demonstrations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241745/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39241745</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.005>10.1016/j.cell.2024.08.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241745</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Carlise Sorenson</dc:creator>
<dc:creator>Katarzyna P Adamala</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Laws of thought in living cells</dc:title>
<dc:identifier>pmid:39241745</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.005</dc:identifier>
</item>
<item>
<title>Harnessing immune cells to leverage PARP inhibitors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241744/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>Homologous-recombination deficiency in DNA repair characterizes a unique group of cancers that are vulnerable to PARP inhibitors and cytotoxic chemotherapy. In this issue of Cell, Luo et al., demonstrated that this genetic attribute in cancer cells may reprogram tumor immune microenvironment and show promise of targeting effector-Treg cells.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4829-4830. doi: 10.1016/j.cell.2024.07.058.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Homologous-recombination deficiency in DNA repair characterizes a unique group of cancers that are vulnerable to PARP inhibitors and cytotoxic chemotherapy. In this issue of Cell, Luo et al., demonstrated that this genetic attribute in cancer cells may reprogram tumor immune microenvironment and show promise of targeting effector-Treg cells.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241744/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39241744</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.058>10.1016/j.cell.2024.07.058</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241744</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Tian-Li Wang</dc:creator>
<dc:creator>Ie-Ming Shih</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Harnessing immune cells to leverage PARP inhibitors</dc:title>
<dc:identifier>pmid:39241744</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.058</dc:identifier>
</item>
<item>
<title>Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241743/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>Early reports suggest that chimeric antigen receptor (CAR)-T therapy has remarkable potential for treating autoimmune disease. Current approaches rely on autologous CAR-T cells, creating a bottleneck to the broad deployment of this therapy. In this issue of Cell, Wang et al.¹ report the first use of allogeneic CAR-T cells in three patients with systemic autoimmune disease.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4826-4828. doi: 10.1016/j.cell.2024.07.056.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Early reports suggest that chimeric antigen receptor (CAR)-T therapy has remarkable potential for treating autoimmune disease. Current approaches rely on autologous CAR-T cells, creating a bottleneck to the broad deployment of this therapy. In this issue of Cell, Wang et al.<sup>1</sup> report the first use of allogeneic CAR-T cells in three patients with systemic autoimmune disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241743/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39241743</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.056>10.1016/j.cell.2024.07.056</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241743</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniel J Baker</dc:creator>
<dc:creator>Carl H June</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Off-the-shelf CAR-T cells could prove paradigm shifting for autoimmune diseases</dc:title>
<dc:identifier>pmid:39241743</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.056</dc:identifier>
</item>
<item>
<title>Deep learning meets histones at the replication fork</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241742/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>Epigenetic inheritance of heterochromatin requires transfer of parental H3-H4 tetramers to both daughter duplexes during replication. Three recent papers exploit yeast genetics coupled to inheritance assays and AlphaFold2-multimer predictions coupled to biochemistry to reveal that a replisome component (Mrc1/CLASPIN) is an H3-H4 tetramer chaperone important for parental histone transfer to daughters.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4824-4826. doi: 10.1016/j.cell.2024.07.055.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Epigenetic inheritance of heterochromatin requires transfer of parental H3-H4 tetramers to both daughter duplexes during replication. Three recent papers exploit yeast genetics coupled to inheritance assays and AlphaFold2-multimer predictions coupled to biochemistry to reveal that a replisome component (Mrc1/CLASPIN) is an H3-H4 tetramer chaperone important for parental histone transfer to daughters.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241742/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39241742</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.07.055>10.1016/j.cell.2024.07.055</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241742</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Hiten D Madhani</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Deep learning meets histones at the replication fork</dc:title>
<dc:identifier>pmid:39241742</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.07.055</dc:identifier>
</item>
<item>
<title>Humans are unreliable models of mouse disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39241741/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>In defying conventional views that dismissed itch as trivial, I persisted in studying basophils and ILC2s in human skin and atopic dermatitis. My research on JAK inhibitors for itch ultimately led to FDA-approved drugs. This is my story of disregarding categories and definitions-a story about an unconventional path in science that emphasizes innovation over conformity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 5;187(18):4814-4818. doi: 10.1016/j.cell.2024.08.006.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In defying conventional views that dismissed itch as trivial, I persisted in studying basophils and ILC2s in human skin and atopic dermatitis. My research on JAK inhibitors for itch ultimately led to FDA-approved drugs. This is my story of disregarding categories and definitions-a story about an unconventional path in science that emphasizes innovation over conformity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39241741/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39241741</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.006>10.1016/j.cell.2024.08.006</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39241741</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Brian S Kim</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Humans are unreliable models of mouse disease</dc:title>
<dc:identifier>pmid:39241741</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.006</dc:identifier>
</item>
<item>
<title>Micro-nanoplastics and cardiovascular diseases: evidence and perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39240674/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>Emerging evidence indicates that chemical exposures in the environment are overlooked drivers of cardiovascular diseases (CVD). Recent evidence suggests that micro- and nanoplastic (MNP) particles derived largely from the chemical or mechanical degradation of plastics might represent a novel CVD risk factor. Experimental data in preclinical models suggest that MNPs can foster oxidative stress, platelet aggregation, cell senescence, and inflammatory responses in endothelial and immune cells while...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 6:ehae552. doi: 10.1093/eurheartj/ehae552. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Emerging evidence indicates that chemical exposures in the environment are overlooked drivers of cardiovascular diseases (CVD). Recent evidence suggests that micro- and nanoplastic (MNP) particles derived largely from the chemical or mechanical degradation of plastics might represent a novel CVD risk factor. Experimental data in preclinical models suggest that MNPs can foster oxidative stress, platelet aggregation, cell senescence, and inflammatory responses in endothelial and immune cells while promoting a range of cardiovascular and metabolic alterations that can lead to disease and premature death. In humans, MNPs derived from various plastics, including polyethylene and polyvinylchloride, have been detected in atherosclerotic plaques and other cardiovascular tissues, including pericardia, epicardial adipose tissues, pericardial adipose tissues, myocardia, and left atrial appendages. MNPs have measurable levels within thrombi and seem to accumulate preferentially within areas of vascular lesions. Their presence within carotid plaques is associated with subsequent increased incidence of cardiovascular events. To further investigate the possible causal role of MNPs in CVD, future studies should focus on large, prospective cohorts assessing the exposure of individuals to plastic-related pollution, the possible routes of absorption, the existence of a putative safety limit, the correspondence between exposure and accumulation in tissues, the timing between accumulation and CVD development, and the pathophysiological mechanisms instigated by pertinent concentrations of MNPs. Data from such studies would allow the design of preventive, or even therapeutic, strategies. Meanwhile, existing evidence suggests that reducing plastic production and use will produce benefits for the environment and for human health. This goal could be achieved through the UN Global Plastics Treaty that is currently in negotiation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39240674/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39240674</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae552>10.1093/eurheartj/ehae552</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39240674</guid>
<pubDate>Fri, 06 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Francesco Prattichizzo</dc:creator>
<dc:creator>Antonio Ceriello</dc:creator>
<dc:creator>Valeria Pellegrini</dc:creator>
<dc:creator>Rosalba La Grotta</dc:creator>
<dc:creator>Laura Graciotti</dc:creator>
<dc:creator>Fabiola Olivieri</dc:creator>
<dc:creator>Pasquale Paolisso</dc:creator>
<dc:creator>Bruno D'Agostino</dc:creator>
<dc:creator>Pasquale Iovino</dc:creator>
<dc:creator>Maria Luisa Balestrieri</dc:creator>
<dc:creator>Sanjay Rajagopalan</dc:creator>
<dc:creator>Philip J Landrigan</dc:creator>
<dc:creator>Raffaele Marfella</dc:creator>
<dc:creator>Giuseppe Paolisso</dc:creator>
<dc:date>2024-09-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Micro-nanoplastics and cardiovascular diseases: evidence and perspectives</dc:title>
<dc:identifier>pmid:39240674</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae552</dc:identifier>
</item>
<item>
<title>Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39236707/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>In 2022, mpox virus (MPXV) spread worldwide, causing 99,581 mpox cases in 121 countries. Modified vaccinia Ankara (MVA) vaccine use reduced disease in at-risk populations but failed to deliver complete protection. Lag in manufacturing and distribution of MVA resulted in additional MPXV spread, with 12,000 reported cases in 2023 and an additional outbreak in Central Africa of clade I virus. These outbreaks highlight the threat of zoonotic spillover by Orthopoxviruses. mRNA-1769, an mRNA-lipid...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Sep 4:S0092-8674(24)00972-3. doi: 10.1016/j.cell.2024.08.043. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In 2022, mpox virus (MPXV) spread worldwide, causing 99,581 mpox cases in 121 countries. Modified vaccinia Ankara (MVA) vaccine use reduced disease in at-risk populations but failed to deliver complete protection. Lag in manufacturing and distribution of MVA resulted in additional MPXV spread, with 12,000 reported cases in 2023 and an additional outbreak in Central Africa of clade I virus. These outbreaks highlight the threat of zoonotic spillover by Orthopoxviruses. mRNA-1769, an mRNA-lipid nanoparticle (LNP) vaccine expressing MPXV surface proteins, was tested in a lethal MPXV primate model. Similar to MVA, mRNA-1769 conferred protection against challenge and further mitigated symptoms and disease duration. Antibody profiling revealed a collaborative role between neutralizing and Fc-functional extracellular virion (EV)-specific antibodies in viral restriction and ospinophagocytic and cytotoxic antibody functions in protection against lesions. mRNA-1769 enhanced viral control and disease attenuation compared with MVA, highlighting the potential for mRNA vaccines to mitigate future pandemic threats.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39236707/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39236707</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.08.043>10.1016/j.cell.2024.08.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39236707</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Eric M Mucker</dc:creator>
<dc:creator>Alec W Freyn</dc:creator>
<dc:creator>Sandra L Bixler</dc:creator>
<dc:creator>Deniz Cizmeci</dc:creator>
<dc:creator>Caroline Atyeo</dc:creator>
<dc:creator>Patricia L Earl</dc:creator>
<dc:creator>Harini Natarajan</dc:creator>
<dc:creator>Genesis Santos</dc:creator>
<dc:creator>Tiffany R Frey</dc:creator>
<dc:creator>Rafael H Levin</dc:creator>
<dc:creator>Anusha Meni</dc:creator>
<dc:creator>Guha A Arunkumar</dc:creator>
<dc:creator>Daniel Stadlbauer</dc:creator>
<dc:creator>Patricia A Jorquera</dc:creator>
<dc:creator>Hamilton Bennett</dc:creator>
<dc:creator>Joshua C Johnson</dc:creator>
<dc:creator>Kath Hardcastle</dc:creator>
<dc:creator>Jeffrey L Americo</dc:creator>
<dc:creator>Catherine A Cotter</dc:creator>
<dc:creator>Jeff W Koehler</dc:creator>
<dc:creator>Christopher I Davis</dc:creator>
<dc:creator>Joshua D Shamblin</dc:creator>
<dc:creator>Kristin Ostrowski</dc:creator>
<dc:creator>Jo Lynne Raymond</dc:creator>
<dc:creator>Keersten M Ricks</dc:creator>
<dc:creator>Andrea Carfi</dc:creator>
<dc:creator>Wen-Han Yu</dc:creator>
<dc:creator>Nancy J Sullivan</dc:creator>
<dc:creator>Bernard Moss</dc:creator>
<dc:creator>Galit Alter</dc:creator>
<dc:creator>Jay W Hooper</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Comparison of protection against mpox following mRNA or modified vaccinia Ankara vaccination in nonhuman primates</dc:title>
<dc:identifier>pmid:39236707</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.08.043</dc:identifier>
</item>
<item>
<title>Transfemoral or surgical aortic valve replacement in young low-risk patients with tricuspid and bicuspid aortic valve stenosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39235157/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Sep 5:ehae537. doi: 10.1093/eurheartj/ehae537. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39235157/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39235157</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae537>10.1093/eurheartj/ehae537</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39235157</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Niklas Schofer</dc:creator>
<dc:creator>Stefan Blankenberg</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Transfemoral or surgical aortic valve replacement in young low-risk patients with tricuspid and bicuspid aortic valve stenosis</dc:title>
<dc:identifier>pmid:39235157</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae537</dc:identifier>
</item>
<item>
<title>Macrophage-Expressed Coagulation Factor 7 Promotes Adverse Cardiac Remodeling</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39234697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Extravascular TF-F7-PAR2 complex signaling drives inflammatory macrophage polarization in ischemic heart disease. Targeting this signaling complex for specific therapeutic macrophage reprogramming following MI attenuates cardiac fibrosis and improves cardiovascular function.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 5. doi: 10.1161/CIRCRESAHA.123.324114. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Excess fibrotic remodeling causes cardiac dysfunction in ischemic heart disease, driven by MAP (mitogen-activated protein) kinase-dependent TGF-ß1 (transforming growth factor-ß1) activation by coagulation signaling of myeloid cells. How coagulation-inflammatory circuits can be specifically targeted to achieve beneficial macrophage reprogramming after myocardial infarction (MI) is not completely understood.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Mice with permanent ligation of the left anterior descending artery were used to model nonreperfused MI and analyzed by single-cell RNA sequencing, protein expression changes, confocal microscopy, and longitudinal monitoring of recovery. We probed the role of the tissue factor (TF)-factor 7 (F7)-integrin ß1-PAR2 (protease-activated receptor 2) signaling complex by utilizing genetic mouse models and pharmacological intervention.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Cleavage-insensitive PAR2<sup>R38E</sup> and myeloid cell integrin ß1-deficient mice had improved cardiac function after MI compared with controls. Proximity ligation assays of monocytic cells demonstrated that colocalization of F7 with integrin ß1 was diminished in monocyte/macrophage F7-deficient mice after MI. Compared with controls, F7<sup>fl/fl</sup> CX3CR1<sup>Cre</sup> mice showed reduced TGF-ß1 and MAP kinase activation, as well as cardiac dysfunction after MI, despite unaltered overall recruitment of myeloid cells. Single-cell mRNA sequencing of CD45 (cluster of differentiation 45)<sup>+</sup> cells 3 and 7 days after MI uncovered a trajectory from recruited monocytes to inflammatory TF<sup>+</sup>/F7<sup>+</sup>/TREM (triggered receptor expressed on myeloid cells) 1<sup>+</sup> macrophages. As early as 7 days after MI, macrophage F7 deletion led to an expansion of reparative Olfml (olfactomedin) 3<sup>+</sup> macrophages and, conversely, to a reduction of TF<sup>+</sup>/F7<sup>+</sup>/TREM1<sup>+</sup> macrophages, which were also reduced in PAR2<sup>R38E</sup> mice. Short-term treatment from days 1 to 5 after nonreperfused MI with a monoclonal antibody inhibiting the macrophage TF-F7-PAR2 signaling complex without anticoagulant activity improved cardiac dysfunction, decreased excess fibrosis, attenuated vascular endothelial dysfunction, and increased survival 28 days after MI.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Extravascular TF-F7-PAR2 complex signaling drives inflammatory macrophage polarization in ischemic heart disease. Targeting this signaling complex for specific therapeutic macrophage reprogramming following MI attenuates cardiac fibrosis and improves cardiovascular function.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39234697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39234697</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324114>10.1161/CIRCRESAHA.123.324114</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39234697</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Venkata Garlapati</dc:creator>
<dc:creator>Qi Luo</dc:creator>
<dc:creator>Jens Posma</dc:creator>
<dc:creator>Melania Aluia</dc:creator>
<dc:creator>Than Son Nguyen</dc:creator>
<dc:creator>Kristin Grunz</dc:creator>
<dc:creator>Michael Molitor</dc:creator>
<dc:creator>Stefanie Finger</dc:creator>
<dc:creator>Gregory Harms</dc:creator>
<dc:creator>Tobias Bopp</dc:creator>
<dc:creator>Wolfram Ruf</dc:creator>
<dc:creator>Philip Wenzel</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Macrophage-Expressed Coagulation Factor 7 Promotes Adverse Cardiac Remodeling</dc:title>
<dc:identifier>pmid:39234697</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324114</dc:identifier>
</item>
<item>
<title>EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39234692/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Endothelial EPAS1 attenuates atherosclerosis at sites of disturbed flow by maintaining EC proliferation via fatty acid uptake and metabolism. This endothelial repair pathway is inhibited in obesity, suggesting a novel triglyceride-PHD2 modulation pathway suppressing EPAS1 expression. These findings have implications for therapeutic strategies addressing vascular dysfunction in obesity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 5. doi: 10.1161/CIRCRESAHA.123.324054. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Atherosclerotic plaques form unevenly due to disturbed blood flow, causing localized endothelial cell (EC) dysfunction. Obesity exacerbates this process, but the underlying molecular mechanisms are unclear. The transcription factor EPAS1 (HIF2A) has regulatory roles in endothelium, but its involvement in atherosclerosis remains unexplored. This study investigates the potential interplay between EPAS1, obesity, and atherosclerosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Responses to shear stress were analyzed using cultured porcine aortic EC exposed to flow in vitro coupled with metabolic and molecular analyses and by en face immunostaining of murine aortic EC exposed to disturbed flow in vivo. Obesity and dyslipidemia were induced in mice via exposure to a high-fat diet or through Leptin gene deletion. The role of <i>Epas1</i> in atherosclerosis was evaluated by inducible endothelial <i>Epas1</i> deletion, followed by hypercholesterolemia induction (adeno-associated virus-PCSK9 [proprotein convertase subtilisin/kexin type 9]; high-fat diet).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: En face staining revealed EPAS1 enrichment at sites of disturbed blood flow that are prone to atherosclerosis initiation. Obese mice exhibited substantial reduction in endothelial EPAS1 expression. Sulforaphane, a compound with known atheroprotective effects, restored EPAS1 expression and concurrently reduced plasma triglyceride levels in obese mice. Consistently, triglyceride derivatives (free fatty acids) suppressed EPAS1 in cultured EC by upregulating the negative regulator PHD2. Clinical observations revealed that reduced serum EPAS1 correlated with increased endothelial PHD2 and PHD3 in obese individuals. Functionally, endothelial EPAS1 deletion increased lesion formation in hypercholesterolemic mice, indicating an atheroprotective function. Mechanistic insights revealed that EPAS1 protects arteries by maintaining endothelial proliferation by positively regulating the expression of the fatty acid-handling molecules CD36 and LIPG to increase fatty acid beta-oxidation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Endothelial EPAS1 attenuates atherosclerosis at sites of disturbed flow by maintaining EC proliferation via fatty acid uptake and metabolism. This endothelial repair pathway is inhibited in obesity, suggesting a novel triglyceride-PHD2 modulation pathway suppressing EPAS1 expression. These findings have implications for therapeutic strategies addressing vascular dysfunction in obesity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39234692/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39234692</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324054>10.1161/CIRCRESAHA.123.324054</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39234692</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pirri</dc:creator>
<dc:creator>Siyu Tian</dc:creator>
<dc:creator>Blanca Tardajos-Ayllon</dc:creator>
<dc:creator>Sophie Irving</dc:creator>
<dc:creator>Francesco Donati</dc:creator>
<dc:creator>Scott P Allen</dc:creator>
<dc:creator>Tadanori Mammoto</dc:creator>
<dc:creator>Gemma Vilahur</dc:creator>
<dc:creator>Lida Kabir</dc:creator>
<dc:creator>Jane Bennett</dc:creator>
<dc:creator>Yasmin Rasool</dc:creator>
<dc:creator>Charis Pericleous</dc:creator>
<dc:creator>Guianfranco Mazzei</dc:creator>
<dc:creator>Liam McAllan</dc:creator>
<dc:creator>William R Scott</dc:creator>
<dc:creator>Thomas Koestler</dc:creator>
<dc:creator>Urs Zingg</dc:creator>
<dc:creator>Graeme Birdsey</dc:creator>
<dc:creator>Clint Miller</dc:creator>
<dc:creator>Torsten Schenkel</dc:creator>
<dc:creator>Emily V Chambers</dc:creator>
<dc:creator>Mark Dunning</dc:creator>
<dc:creator>Jovana Serbanovic-Canic</dc:creator>
<dc:creator>Francesco Botrè</dc:creator>
<dc:creator>Akiko Mammoto</dc:creator>
<dc:creator>Suowen Xu</dc:creator>
<dc:creator>Elena Osto</dc:creator>
<dc:creator>Weiping Han</dc:creator>
<dc:creator>Maria Fragiadaki</dc:creator>
<dc:creator>Paul C Evans</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>EPAS1 Attenuates Atherosclerosis Initiation at Disturbed Flow Sites Through Endothelial Fatty Acid Uptake</dc:title>
<dc:identifier>pmid:39234692</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324054</dc:identifier>
</item>
<item>
<title>Disparities in Emergency Medical Services Use, Prehospital Notification, and Symptom Onset to Arrival in Patients With Acute Stroke</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39234678/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In this national cross-sectional study, Black race was associated with prolonged onset to time of arrival intervals and significantly decreased odds of EMS prehospital notification, despite similar use of EMS transport. Greater county-level deprivation was also associated with reduced odds of EMS prehospital notification and slightly prolonged stroke symptom onset to emergency department arrival time. Efforts to reduce place-based disparities in stroke care must address significant...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Sep 5. doi: 10.1161/CIRCULATIONAHA.124.070694. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Disparities in time to hospital presentation and prehospital stroke care may be important drivers in inequities in acute stroke treatment rates, functional outcomes, and mortality. It is unknown how patient-level factors, such as race and ethnicity and county-level socioeconomic status, affect these aspects of prehospital stroke care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Cross-sectional study of patients with ischemic stroke, intracerebral hemorrhage, and subarachnoid hemorrhage in the Get With the Guidelines-Stroke registry, presenting from July 2015 to December 2019, with symptom onset &lt;24 hours. Multivariable logistic regression and quantile regression were used to investigate the outcomes of interest: emergency medical services (EMS) transport (versus private vehicle), EMS prehospital notification (versus no prehospital notification), and stroke symptom onset to time of arrival at the emergency department. Prespecified covariates included patient-level, hospital-level, and county-level characteristics.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The inclusion criteria was met by the 606 369 patients. Of the patients, 51.2% were men and 69.9% White, with a median National Institutes of Health Stroke Severity of 4 (IQR, 2-10), and median social deprivation index (SDI) of 51 (IQR, 27-75). Median symptom onset to arrival time was 176 minutes (IQR, 64-565). Black race was significantly associated with prolonged symptom onset to emergency department arrival time (+28.21 minutes [95% CI, 25.59-30.84]), and decreased odds of EMS prehospital notification (OR, 0.80 [95% CI, 0.78-0.82]). SDI was not associated with differences in EMS use but was associated with lower odds of EMS prehospital notification (upper SDI tercile versus lowest, OR, 0.79 [95% CI, 0.78-0.81]). SDI was also significantly associated with stroke symptom onset to emergency department arrival time (upper SDI tercile versus lowest +2.56 minutes [95% CI, 0.58-4.53]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In this national cross-sectional study, Black race was associated with prolonged onset to time of arrival intervals and significantly decreased odds of EMS prehospital notification, despite similar use of EMS transport. Greater county-level deprivation was also associated with reduced odds of EMS prehospital notification and slightly prolonged stroke symptom onset to emergency department arrival time. Efforts to reduce place-based disparities in stroke care must address significant inequities in prehospital care of acute stroke and continue to address health inequities associated with race and ethnicity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39234678/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39234678</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.070694>10.1161/CIRCULATIONAHA.124.070694</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39234678</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Regina Royan</dc:creator>
<dc:creator>Brian Stamm</dc:creator>
<dc:creator>Timmy Lin</dc:creator>
<dc:creator>Janette Baird</dc:creator>
<dc:creator>Christopher Becker</dc:creator>
<dc:creator>Rebecca Karb</dc:creator>
<dc:creator>Tina Burton</dc:creator>
<dc:creator>Dawn Kleindorfer</dc:creator>
<dc:creator>Shyam Prabhakaran</dc:creator>
<dc:creator>Tracy E Madsen</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Disparities in Emergency Medical Services Use, Prehospital Notification, and Symptom Onset to Arrival in Patients With Acute Stroke</dc:title>
<dc:identifier>pmid:39234678</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.070694</dc:identifier>
</item>
<item>
<title>Experimental TET2 Clonal Hematopoiesis Predisposes to Renal Hypertension Through an Inflammasome-Mediated Mechanism</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39234670/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Tet2-mediated CH sensitizes mice to a hypertensive stimulus. Mechanistically, the expansion of hematopoietic Tet2-deficient cells promotes hypertension due to elevated renal immune cell infiltration and activation of the NLRP3 inflammasome, with consequences on sodium retention. These data indicate that carriers of TET2 CH could be at elevated risk for the development of hypertension and that immune modulators could be useful in treating hypertension in this patient population.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Sep 5. doi: 10.1161/CIRCRESAHA.124.324492. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hypertension incidence increases with age and represents one of the most prevalent risk factors for cardiovascular disease. Clonal events in the hematopoietic system resulting from somatic mutations in driver genes are prevalent in elderly individuals who lack overt hematologic disorders. This condition is referred to as age-related clonal hematopoiesis (CH), and it is a newly recognized risk factor for cardiovascular disease. It is not known whether CH and hypertension in the elderly are causally related and, if so, what are the mechanistic features.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS AND RESULTS: A murine model of adoptive bone marrow transplantation was employed to examine the interplay between Tet2 (ten-eleven translocation methylcytosine dioxygenase 2) CH and hypertension. In this model, a subpressor dose of Ang II (angiotensin II) resulted in elevated systolic and diastolic blood pressure as early as 1 day after the challenge. These conditions led to the expansion of Tet2-deficient proinflammatory monocytes and bone marrow progenitor populations. Tet2-deficiency promoted renal CCL5 chemokine expression and macrophage infiltration into the kidney. Consistent with macrophage involvement, Tet2-deficiency in myeloid cells promoted hypertension when mice were treated with a subpressor dose of Ang II. The hematopoietic Tet2<sup>-</sup><sup>/-</sup> condition led to sodium retention, renal inflammasome activation, and elevated levels of IL (interleukin)-1β and IL-18. Analysis of the sodium transporters indicated NCC (Na<sup>+</sup>-Cl<sup>-</sup> cotransporter) and NKCC2 activation at residues Thr53 and Ser105, respectively. Administration of the NLRP3 inflammasome inhibitor MCC950 reversed the hypertensive state, sodium retention, and renal transporter activation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Tet2-mediated CH sensitizes mice to a hypertensive stimulus. Mechanistically, the expansion of hematopoietic Tet2-deficient cells promotes hypertension due to elevated renal immune cell infiltration and activation of the NLRP3 inflammasome, with consequences on sodium retention. These data indicate that carriers of TET2 CH could be at elevated risk for the development of hypertension and that immune modulators could be useful in treating hypertension in this patient population.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39234670/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39234670</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.324492>10.1161/CIRCRESAHA.124.324492</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39234670</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ariel H Polizio</dc:creator>
<dc:creator>Lucila Marino</dc:creator>
<dc:creator>Kyung-Duk Min</dc:creator>
<dc:creator>Yoshimitsu Yura</dc:creator>
<dc:creator>Luca Rolauer</dc:creator>
<dc:creator>Jesse D Cochran</dc:creator>
<dc:creator>Megan A Evans</dc:creator>
<dc:creator>Eunbee Park</dc:creator>
<dc:creator>Heather Doviak</dc:creator>
<dc:creator>Emiri Miura-Yura</dc:creator>
<dc:creator>Miranda E Good</dc:creator>
<dc:creator>Abigail G Wolpe</dc:creator>
<dc:creator>Maria Grandoch</dc:creator>
<dc:creator>Brant Isakson</dc:creator>
<dc:creator>Kenneth Walsh</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Experimental TET2 Clonal Hematopoiesis Predisposes to Renal Hypertension Through an Inflammasome-Mediated Mechanism</dc:title>
<dc:identifier>pmid:39234670</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.324492</dc:identifier>
</item>
<item>
<title>Exploring the Need for Precise MI Adjudication in Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39233110/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Aug 26:S0735-1097(24)08277-9. doi: 10.1016/j.jacc.2024.08.046. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39233110/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39233110</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.08.046>10.1016/j.jacc.2024.08.046</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39233110</guid>
<pubDate>Thu, 05 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael J Blaha</dc:creator>
<dc:creator>Andrew P DeFilippis</dc:creator>
<dc:date>2024-09-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Exploring the Need for Precise MI Adjudication in Clinical Trials</dc:title>
<dc:identifier>pmid:39233110</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.08.046</dc:identifier>
</item>
<item>
<title>Reply: Significance of B-type Natriuretic Peptide Level in Patients With Small Left Ventricle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232640/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e89. doi: 10.1016/j.jacc.2024.06.030.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232640/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39232640</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.030>10.1016/j.jacc.2024.06.030</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232640</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Mingxiao Li</dc:creator>
<dc:creator>Liu He</dc:creator>
<dc:creator>Lan Ren</dc:creator>
<dc:creator>Caihua Sang</dc:creator>
<dc:creator>Changsheng Ma</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Significance of B-type Natriuretic Peptide Level in Patients With Small Left Ventricle</dc:title>
<dc:identifier>pmid:39232640</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.030</dc:identifier>
</item>
<item>
<title>Significance of B-Type Natriuretic Peptide Level in Patients With Small Left Ventricle</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232639/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e87. doi: 10.1016/j.jacc.2024.05.071.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232639/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39232639</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.05.071>10.1016/j.jacc.2024.05.071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232639</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Tomoaki Murakami</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Significance of B-Type Natriuretic Peptide Level in Patients With Small Left Ventricle</dc:title>
<dc:identifier>pmid:39232639</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.05.071</dc:identifier>
</item>
<item>
<title>Reply: Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232638/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e85-e86. doi: 10.1016/j.jacc.2024.06.031.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232638/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39232638</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.031>10.1016/j.jacc.2024.06.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232638</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Ziwen Li</dc:creator>
<dc:creator>Ryan Wereski</dc:creator>
<dc:creator>Nicholas L Mills</dc:creator>
<dc:creator>Dorien M Kimenai</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</dc:title>
<dc:identifier>pmid:39232638</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.031</dc:identifier>
</item>
<item>
<title>Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232637/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e83-e84. doi: 10.1016/j.jacc.2024.04.071.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232637/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39232637</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.04.071>10.1016/j.jacc.2024.04.071</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232637</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Amy G Huebschmann</dc:creator>
<dc:creator>Nanette K Wenger</dc:creator>
<dc:creator>C Noel Bairey Merz</dc:creator>
<dc:creator>Allan S Jaffe</dc:creator>
<dc:creator>Larry A Allen</dc:creator>
<dc:creator>Stacy A Trent</dc:creator>
<dc:creator>Judith G Regensteiner</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Potential for Misapplication of a Uniform vs Sex-Specific High-Sensitivity Cardiac Troponin Threshold</dc:title>
<dc:identifier>pmid:39232637</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.04.071</dc:identifier>
</item>
<item>
<title>Reply: The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232636/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e81. doi: 10.1016/j.jacc.2024.06.032.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232636/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39232636</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.06.032>10.1016/j.jacc.2024.06.032</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232636</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>Yun Gi Kim</dc:creator>
<dc:creator>Hyoung Seok Lee</dc:creator>
<dc:creator>Hoseob Kim</dc:creator>
<dc:creator>Jong-Il Choi</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</dc:title>
<dc:identifier>pmid:39232636</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.06.032</dc:identifier>
</item>
<item>
<title>The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39232635/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240907205245&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2024 Sep 10;84(11):e79. doi: 10.1016/j.jacc.2024.03.434.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39232635/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240907205245&v=2.18.0.post9+e462414">39232635</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.03.434>10.1016/j.jacc.2024.03.434</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39232635</guid>
<pubDate>Wed, 04 Sep 2024 06:00:00 -0400</pubDate>
<dc:creator>James A Reiffel</dc:creator>
<dc:date>2024-09-04</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation</dc:title>
<dc:identifier>pmid:39232635</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.03.434</dc:identifier>
</item>





























</channel>
</rss>